Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer [SUBSTUDY OF 700216591]

Trial Profile

Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer [SUBSTUDY OF 700216591]

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary) ; Carboplatin; Gemcitabine
  • Indications Carcinoma; Early breast cancer; Triple negative breast cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms ADAPT; WSG-ADAPT TN
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 23 Mar 2023 Planned End Date changed from 1 May 2020 to 1 Oct 2024.
    • 02 Sep 2022 Results assessing the impact of stromal tumor-infiltrating lymphocytes dynamics during neoadjuvant chemotherapy on pCR and survival in triple-negative early breast cancer, published in the Breast Cancer Research.
    • 08 Jun 2021 Results of a NGS-based mutational analysis assessing distribution of tumor mutations in BC-associated genes and impact of BRCA mutation status on pCR and outcome ; performed on DNA derived from pretreatment FFPE samples presented at the 57th Annual Meeting of the American Society of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top